Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Help Rheumatology Research Foundation Hit Its Year-End Goal: $100,000

  |  

The Rheumatology Research Foundation is the charitable arm of the ACR, advancing research and training to improve the health of people living with rheumatic disease. Thanks to the continued support of ACR and ARP members, the Foundation is the largest private funding source for rheumatology research and training programs in the U.S. In all, the…

Rheum After 5: Dr. Stacy Ardoin & Mr. Mom

  |  

In 2004, Stacy Ardoin, MD, MHS, became pregnant with twins during the second year of her fellowship at Duke University School of Medicine, Durham, N.C. Although she and her husband, Adrien, were thrilled by the news, the astronomical cost of day care for two infants was a specter. At the time, Adrien managed a book­store…

LeoWolfert / shutterstock.com

Legal Updates: Tips for Protecting Your Patients’ Health Information

  |  

In the daily shuffle of evaluating patients and focusing on the delivery of high-quality patient care, the importance of protecting patient information may get overlooked. Human error is just one possible way patient information can be compromised. Cybersecurity attacks are becoming more numerous and sophisticated every day, with the number of patient records compromised increasing….

Fall 2019’s Awards, Appointments & Announcements in Rheumatology

  |  

J. Michelle Kahlenberg Receives Presidential Early Career Award for Scientists & Engineers (PECASE) A physician scientist and associate professor of internal medicine in the Division of Rheumatology at the University of Michigan in Ann Arbor, J. Michelle Kahlenberg, MD, PhD, is a 2019 recipient of the prestigious PECASE award. Dr. Kahlenberg, who also holds the…

Ankylosing Spondylitis & Uveitis: An Ophthalmologist’s Perspective

  |  

It’s often said the eyes are the window to the soul, and in the case of ankylosing spondylitis and other spondylo­arthropathies, one can also say the eyes are the window to systemic disease. Although uveitis occurs in approximately 2–5% of patients with inflammatory bowel disease, 6–9% of patients with psoriatic arthritis and 25% of patients…

Lessons from Master Clinicians: An Interview with Dr. Paul Plotz

  |  

Rheumatologists who are outstanding clinicians, provide consistently exceptional care to patients and serve as role models for colleagues and trainees are in the spotlight in our Lessons from a Master Clinician series. Here, we offer insights from clinicians who have achieved a level of distinction in the field of rheumatology. Paul Plotz, MD, is scientist…

The 2019 ACR Award Winners & Distinguished Fellows

  |  

ATLANTA—Every year at its Annual Meeting, the ACR recognizes its members’ outstanding contributions to the field of rheumatology through an awards program. The ACR is proud to announce 20 award recipients for 2019, honored for their accomplishments as clinicians, instructors or researchers who have helped advance rheumatology, for their commitment to inspire others to enter…

Meet the Incoming Arthritis & Rheumatology Editor in Chief, Dr. Daniel Solomon

  |  

Daniel Solomon, MD, MPH, has practiced rheumatology for more than 20 years, all while conducting translational and clinical research and teaching young clinicians. Soon, he will also step into the role of editor in chief of Arthritis & Rheumatology, as Richard J. Bucala, MD, PhD, ends his tenure. He will assume some duties during a…

Hair dye being applied to a man’s beard.

Case Report: A 50-Year-Old Man Suffers Dye-Induced Arthritis

Hrudya Abraham, MD, Eric Warm, MD, FACP, & Avis Ware, MD  |  

Hair dye products are commonly used by both men and women to enhance youth and beauty and to follow fashion trends. As reported in the medical literature, hair dyes and their ingredients are associated with allergic contact dermatitis. A possible association with joint inflammation has also been recognized. There is literature to support that para-phenylenediamine…

FDA Approves Nintedanib for SSc-ILD, But Temper Your Expectations

Michael Putman, MD  |  

The U.S. Food & Drug Admin­istration (FDA) approved nintedanib for systemic sclerosis associated interstitial lung disease (SSc-ILD) on Sept. 6 after a randomized, controlled trial (SENSCIS) demonstrated significant benefit against placebo.1 At a cost of $96,000 per year, treatment reduced the adjusted annual rate of change in forced vital capacity (FVC) from –93.3 mL in…